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Introduction: There is evidence that patients suffering from chronic hepatic diseases, includ-
ing  chronic hepatitis B and chronic hepatitis C, have a reduced health-related quality of life.
The  aim of this study was to evaluate the impact of the notiﬁcation of test results for hepatitis
B  and hepatitis C on the quality of life of blood donors.
Methods: Over a 29-month period, this study assessed the quality of life of 105 blood donors
with  positive serological screening tests for hepatitis B and hepatitis C and donors who
presented false-positive test results. The Medical Outcome Study 36-Item Short Form Health
Survey Questionnaire was applied at three time points: (1) when an additional blood sample
was  collected for conﬁrmatory tests; (2) when donors were notiﬁed about their serological
status; and (3) when donors, positive for hepatitis B and hepatitis C, started clinical follow-
up.  Quality of life scores for the conﬁrmed hepatitis B and hepatitis C groups were compared
to  the false-positive control group.
Results: The domains bodily pain, general health perception, social function, and mental
health and the physical component improved signiﬁcantly in donors with hepatitis C from
Time  Point 1 to Time Point 3. Health-related quality of life scores of donors diagnosed with
hepatitis B and hepatitis C were signiﬁcantly lower in six and four of the eight domains,
respectively, compared to the false-positive control group.
Conclusion: A decreased quality of life was detected before and after diagnosis in blood
donors with hepatitis B and hepatitis C. Contrary to hepatitis B positive donors, the pos-
sibility of medical care may have improved the quality of life among hepatitis C positive
donors.
© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published∗ Corresponding author at: Rua Pedroso Alvarenga, 86, apt 43, Itaim Bib
E-mail address: porto-ferreira@uol.com.br (F.A.P. Ferreira).
ttp://dx.doi.org/10.1016/j.bjhh.2015.08.004
516-8484/© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia
eserved.by Elsevier Editora Ltda. All rights reserved.i, 04531-011 São Paulo, SP, Brazil.
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.382  rev bras hematol hem
Introduction
Hepatitis B (HBV) and hepatitis C (HCV) are major public
health problems with 350 million and 150 million infections
worldwide, respectively.1 Due to their asymptomatic devel-
opment, their diagnosis often occurs during blood donation.
The prevalence of concordant HBsAg and anti-HBc tests is 213
per 100,000 donations in São Paulo, while conﬁrmed anti-HCV
reactivity is 287 per 100,000 donations.2 Several studies have
shown that patients with HBV or HCV may present emotional,
social or psychological disorders that can impact their health-
related quality of life (HRQOL) even when asymptomatic or in
the presence of minor symptoms.3,4
HRQOL refers to a patient’s subjective assessment or
perception of his/her complete physical, mental and social
well-being, including a range of conditions not limited to med-
ical interventions.5 The assessment of HRQOL has proven to
be an effective tool to understand the subjective impact that
diseases have on patients. Several instruments are available
to evaluate the biomedical and psychosocial aspects used to
measure HRQOL. These instruments are classiﬁed as generic
or speciﬁc.6 Generic instruments can be universally applied
and allow comparisons between different diseases or different
populations. Speciﬁc instruments are capable of estimating
the quality of life associated with speciﬁc aspects of dis-
eases (e.g., diabetes or asthma), populations (e.g., seniors) or
functions (e.g., functional capacity or sexual function). The
instrument most commonly used to measure HRQOL is the
Medical Outcome Study 36-Item Short Form Health Survey (SF-
36), which is a generic instrument with questions divided into
eight domains. Answers are converted into numerical values,
with higher scores representing better HRQOL.7
Generally, HRQOL is impaired in patients with chronic liver
disease regardless of the etiology, and the level of the scores
has been associated with disease severity. In HCV where
HRQOL has been most studied, it has been proposed that
the mere  presence of HCV causes a drop in quality of life.8
Moreover, a notable decrease in HRQOL has been detected
in HCV-positive blood donors unaware of their condition.9
Another hypothesis is that the impact of the diagnosis of hep-
atitis C causes a reduction in HRQOL in carriers.10 For hepatitis
B, HRQOL studies are more  frequent in endemic areas such
as regions of immigrants from Korea11 and in patients from
Singapore.12
The aim of this study is to evaluate the impact of the
diagnosis of HBV and HCV on HRQOL during the notiﬁcation
and counseling process in a population of seropositive blood
donors.
Methods
Population
Blood donors with positive serological screening tests for
HBV (concomitant HBsAg and anti-HBc) and HCV (enzyme
immunoassay – EIA) were recruited among donors who
returned for perform conﬁrmatory tests.
Routinely, when a donor presents a positive serologic test,
a letter is sent within 30 days inviting him/her to return to 2 0 1 5;3  7(6):381–387
the blood bank for additional laboratory tests. Upon retur-
ning to the blood center, a new blood sample is collected
and conﬁrmatory tests are performed. For the purpose of
this study, donors were considered HBV-positive if they were
repeat-reactive for both HBsAg EIA and anti-HBc EIA in the
screening and conﬁrmatory samples. Donors were considered
HCV-positive if the anti-HCV EIA tests were repeat-reactive at
the time of donation and in the conﬁrmatory follow-up sample
and the immunoblot was positive in the conﬁrmatory sample.
Donors were considered to be false-positive for HCV when
the anti-HCV EIA test was positive or borderline at the time
of donation and the conﬁrmatory test and immunoblot were
negative in the conﬁrmatory sample. After conﬁrmatory tests,
donors were notiﬁed and counseled about the results. Those
who were conﬁrmed to be HBV or HCV positive were referred to
a government healthcare clinic specializing in hepatitis care
for additional evaluation, laboratory tests, liver biopsies and
treatment when necessary.
The inclusion criterion was HBV or HCV-positive blood
donors who completed the three phases of the study and
false-positive donors who completed the ﬁrst two  phases.
The exclusion criteria were (1) donors who were previously
aware of their serological status for HBV and HCV; (2) donors
with positive serologic screening tests for human immuno-
deﬁciency virus infection (HIV), human T-lymphotropic virus
type 1 and 2 (HTLV-1/2), syphilis, or Chagas disease; (3)
donors with concomitant reactive serologic screening tests for
HBV and HCV; and (4) donors who presented anti-HCV EIA
repeat-reactive or inconclusive results and an indeterminate
immunoblot at the conﬁrmatory test.
After the conﬁrmatory tests, the participants were divided
into three groups: (1) HBV-positive; (2) HCV-positive and (3)
False-positive controls.
Study  design
Prospective cohort collection of sequential HRQOL data was
carried out at three time points. SF-36 questionnaires were
applied for all phases, and scores among donors diagnosed
with HBV and HCV and the false-positive group were com-
pared. After obtaining informed consent, in the ﬁrst phase,
donors were asked to ﬁll out the SF-36 when they returned for
retesting. For illiterate donors, questionnaires were applied by
trained physicians. In the second phase, donors who were con-
ﬁrmed as HBV or HCV positive after retesting were informed
about their serologic status and asked to ﬁll out the SF-36 ques-
tionnaire a second time. Donors who presented false-positive
screening test proﬁles were also asked to ﬁll out the SF-36
questionnaire at this time (false-positive control group). In the
third phase, blood donors diagnosed with HBV or HCV were
subjected to a clinical evaluation at a referral center after a 30
to 60-day interval and asked to ﬁll out the SF-36 for the third
time. Figure 1 shows the different phases of the protocol to
which blood donors were subjected during the study.
The generic instrument used to assess the HRQOL (SF-36)
can be applied to any disease and even to healthy subjects.13SF-36 measures HRQOL in the previous four weeks and con-
sists of 36 questions divided into eight domains: physical
functioning, physical role, bodily pain, general health percep-
tion, vitality, social functioning, emotional role and mental
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ealth. SF-36 scores were also analyzed in the form of a range
ummarized as physical and mental components. The physi-
al component is formed by the domains physical functioning,
hysical role, bodily pain and general health perception, while
he mental component is formed by the domains vitality,
ocial functioning, emotional role and mental health. Possible
cores vary from zero to one hundred with the highest score
orresponding to the best quality of life.
tatistical  analysis
he nonparametric Friedman test was used to compare means
nd standard deviations for each domain of the SF-36 of the
BV and HCV groups at Time Points 1, 2 and 3. The Wilcoxon
est was used to compare means of the two hepatitis groups at
he ﬁrst and second Time Points with the mean scores for each
omain of the SF-36 of donors who presented false-positive
esults. The signiﬁcance level was set at 5% (p-value ≤ 0.05).
aboratory  methods
aboratory testing was performed at the Serology Division of
he Fundac¸ão Pró-São Paulo Hemocentro de São Paulo fol-
owing usual blood bank procedures for HBV surface antigen,
BV core antibody, syphilis, anti-HCV, anti-HTLV-1/2, Chagas
isease, and anti-HIV-1 and -2. Serologic reactive units were ﬂow chart.
discarded according to institution policy.14 Donors who  pre-
sented any positive screening test results were contacted to
collect another sample.
The Enzygnost HBsAg 5.0 (Siemens, Marburg, Germany)
and Enzygnost Anti-HBc monoclonal (Siemens, Marburg, Ger-
many)  tests were used for HBV screening and conﬁrmatory
tests and the Murex anti-HCV version 4.0 (Abbott, South
Africa) test was used for HCV screening. An immunoblot (CHI-
RON RIBA HCV 3.0 S/A, Emeryville, USA) was used for the HCV
conﬁrmatory test.
Results
Over a period of 29 months, 211 blood donors with reac-
tive screening tests for HBV and HCV were enrolled. Among
them, 32 were diagnosed with HBV, 35 with HCV and 38
had screening tests that were reactive for HCV that were not
conﬁrmed in the additional conﬁrmatory test and were con-
sidered false-positive results. The remaining 106 (50%) donors
with reactive serologic screening tests for HBV or HCV did not
complete all the phases of the follow-up and were excluded.Demographic data of the donors diagnosed with HBV, HCV
and false-positive results are described in Table 1. There was
a signiﬁcant difference in age between the false-positive con-
trols (average 31.5 ± 7 years) and the HBV (36.2 ± 9.7 years)
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Table 1 – Gender, ethnicity and age of blood donors with hepatitis B and hepatitis C compared to a control group of blood
donors with false-positive results.
Hepatitis B
(n = 32)
p-Value Hepatitis C
(n = 35)
p-Value False-positive controls
(n = 38)
Gender – n (%) 0.438 0.312
Male 22 (68.7) 20 (57.1) 23 (60.5)
Female 10 (31.2) 15 (42.9) 15 (39.5)
Ethnicity – n (%) 0.745 0.681
White 13 (40.6) 19  (54.2) 21 (55.3)
Black 8 (25.0) 8  (22.8) 6  (15.8)
Mixed 11 (34.4) 8  (22.8) 11 (28.9)
Age 0.046 0.030
Mean 36.2 ± 9.7 37.1 ± 10.8 31.5 ± 7.0
role (p-value = 0.042) and at Time Point 2 for physicalMedian 37.5 
Range 19–55 
and HCV (37.1 ± 10.8 years) groups (p-value = 0.046 and p-
value = 0.03, respectively).
Longitudinal  analysis  using  the  Medical  Outcome  Study
36-Item  Short  Form  Health  Survey
There was an improvement in HRQOL in the group of donors
diagnosed with HCV in the bodily pain (p-value = 0.011), gen-
eral health perception (p-value <0.001), social functioning
(p-value = 0.019), and mental health domains (p-value = 0.033)
and the physical component (p-value = 0.007) of the SF-36
summarized scale. In contrast, there were no signiﬁcant dif-
ferences in the longitudinal analysis of all studied domains of
donors diagnosed with HBV (Tables 2 and 3).
Comparison  between  group  of  donors  with  hepatitis  B  and
C and  the  false-positive  control  group
Donors  with  HBV  versus  donors  with  HCV
Using the SF-36 questionnaire prior to conﬁrmation of the
infection (Time Point 1), there were no signiﬁcant differences
for any of the eight domains or for the physical and mental
components of the summary scale between the HBV-positive
and HCV-positive blood donors.
Table 2 – Scores for the different domains and components of t
Survey (SF-36) during the longitudinal analysis of donors with 
SF-36
domain
Time  point 1 Tim
PF 84.8 ± 19.3 8
PR 80.4 ± 34.6 8
BP 71.9 ± 25.5 7
GHP 70.6 ± 16.4 6
VIT 72.9 ± 18.4 7
SF 85.6 ± 16.5 8
ER 78.1 ± 34.5 8
MH 78.3 ± 16.7 7
PC 51.0 ± 7.4 5
MC 51.0 ± 10.3 5
PF: physical functioning; PR: physical role; BP: bodily pain; GHP: general h
role; MH: mental health; PC: physical component; MC: mental component
Scores shown as means and standard deviation.36.0 29.0
18–57 21–49
Donors  with  HBV  diagnosis  versus  the  false-positive  control
group
At Time Point 1, a signiﬁcantly higher mean was found
for the false-positive control group compared to the HBV-
positive donors for the physical role domain (p-value = 0.032)
only. At Time Point 2 however, the false-positive con-
trol group had signiﬁcantly higher means for physical
functioning (p-value = 0.006), physical role (p-value = 0.006),
bodily pain (p-value = 0.006), vitality (p-value = 0.017), emo-
tional role (p-value = 0.038), and mental health (p-value = 0.030)
and both the physical (p-value = 0.019) and mental compo-
nents (p-value = 0.022) compared to the HBV-positive donors
(Table 4).
Donors  diagnosed  with  HCV  versus  the  false-positive  control
group
The false-positive control group presented signiﬁcantly
higher means compared to HCV-positive donors at Time
Point 1 for physical role (p-value = 0.040) and emotionalrole (p-value = 0.010), vitality (p-value = 0.037), social func-
tioning (p-value = 0.010) and emotional role (p-value = 0.005)
(Table 5).
he Medical Outcome Study 36-Item Short Form Health
hepatitis B (n = 32).
e point 2 Time point 3 p-Value
4.1 ± 17.3 84.1 ± 17.2 0.988
0.5 ± 33.4 80.5 ± 29.7 0.878
4.8 ± 18.1 68 ± 25.2 0.084
8.9 ± 16.4 69.9 ± 18.4 0.775
9.5 ± 22.8 67.3 ± 21.5 0.549
9.6 ± 18.5 85.3 ± 23.8 0.731
2.3 ± 30.5 77.1 ± 34.4 0.946
4.3 ± 17.1 75.1 ± 16.9 0.801
0.9 ± 7.7 51.6 ± 7.5 0.943
1.2 ± 8.7 50.2 ± 10.2 0.929
ealth perception; VIT: vitality; SF: social functioning; ER: emotional
.
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Table 3 – Scores for the different domains and components of the Medical Outcome Study 36-Item Short Form Health
Survey (SF-36) during the longitudinal analysis of donors with hepatitis C (n = 35).
SF-36 domain Time point 1 Time point 2 Time point 3 p-Value
PF 89.3 ± 14.7 89.7 ± 15.5 91.7 ± 11.2 0.251
PR 90.0 ± 16.3 83.6 ± 22.0 87.1 ± 26.0 0.157
BP 76.4 ± 21.0 80.5 ± 22.0 83.2 ± 17.5 0.011
GHP 70.6 ± 14.6 69.0 ± 18.0 76.8 ± 16.3 <0.001
VIT 72.7 ± 19.9 70.6 ± 20.9 72.3 ± 20.9 0.108
SF 77.3 ± 26.8 76.5 ± 25.6 84.7 ± 27.3 0.019
ER 78.1 ± 31.3 77.2 ± 34.0 79.1 ± 31.4 0.148
MH 74.8 ± 21.4 77.1 ± 19.7 78.3 ± 18.8 0.007
PC 53.0 ± 6.0 53.2 ± 6.9 54.9 ± 5.8 0.007
MC 50.2 ± 10.7 50.1 ± 11.4 51.7 ± 10.7 0.146
PF: physical functioning; PR: physical role; BP: bodily pain; GHP: general health perception; VIT: vitality; SF: social functioning; ER: emotional
role; MH: mental health; PC: physical component; MC: mental component.
Scores shown as means and standard deviation.
Table 4 – Scores for each domain and component of the Medical Outcome Study 36-Item Short Form Health Survey
(SF-36) comparing donors with hepatitis B and false-positive controls.
SF-36 domain Time point 1 Time point 2
HBV FP p-Value HBV FP p-Value
(n = 32) (n = 38) Wilcoxon (n = 32) (n = 38) Wilcoxon
PF 84.8 ± 14.7 91.1 ± 12.4 0.162 84.1 ± 17.3 93.9 ± 8.1 0.006
PR 80.4 ± 34.6 93.4 ± 23.0 0.032 80.5 ± 33.4 96.7 ± 10.4 0.006
BP 71.9 ± 25.5 78.7 ± 22.2 0.309 74.8 ± 18.1 86.6 ± 16.3 0.006
GHP 70.6 ± 14.6 70.1 ± 11.5 0.939 68.9 ± 16.4 71.5 ± 13.2 0.343
VIT 72.9 ± 18.4 74.1 ± 18.4 0.586 68.0 ± 22.9 80.4 ± 16.1 0.017
SF 85.6 ± 16.5 86.0 ± 20.7 0.495 89.6 ± 18.5 90.6 ± 18.4 0.367
ER 78.1 ± 34.5 90.4 ± 23.1 0.103 82.3 ± 30.5 93.0 ± 23.4 0.038
MH 78.3 ± 16.7 78.4 ± 15.7 0.924 74.3 ± 17.1 81.5 ± 15.5 0.030
PC 51.0 ± 7.4 53.5 ± 5.0 0.154 51.0 ± 7.7 55.1 ± 3.3 0.019
MC 51.0 ± 10.3 52.4 ± 8.8 0.513 51.2 ± 8.7 54.1 ± 9.4 0.022
HBV: hepatitis B group; FP: false-positive group; PF: physical functioning; PR: physical role; BP: bodily pain; GHP: general health perception; VIT:
vitality; SF: social functioning; ER: emotional role; MH: mental health; PC: physical component; MC: mental component.
Scores shown as means and standard deviation.
Table 5 – Scores for each domain and component of the Medical Outcome Study 36-Item Short Form Health Survey
(SF-36) comparing donors with hepatitis C and false-positive controls.
SF-36 domain Time point 1 Time point 2
HCV FP p-Value HCV FP p-Value
(n = 35) (n = 38) Wilcoxon (n = 35) (n = 38) Wilcoxon
PF 89.3 ± 14.7 91.1 ± 12.4 0.771 89.7 ± 15.5 93.9 ± 8.1 0.587
PR 90.0 ± 16.7 93.4 ± 23.0 0.040 83.6 ± 27.1 96.7 ± 10.4 0.010
BP 76.4 ± 21.1 78.7 ± 22.2 0.608 80.5 ± 22.1 86.6 ± 16.3 0.319
GHP 70.6 ± 14.6 70.1 ± 11.5 0.969 69.0 ± 18.1 71.5 ± 13.2 0.444
VIT 72.7 ± 19.9 74.1 ± 18.1 0.842 70.6 ± 21.0 80.4 ± 16.1 0.037
SF 77.3 ± 26.8 86.0 ± 20.7 0.125 76.5 ± 25.6 90.6 ± 18.4 0.010
ER 78.1 ± 31.3 90.4 ± 23.1 0.042 77.2 ± 34.1 93.0 ± 23.4 0.005
MH 74.8 ± 21.4 78.3 ± 15.7 0.743 77.1 ± 19.7 81.5 ± 15.5 0.446
PC 53.1 ± 6.0 53.5 ± 5.0 0.921 53.2 ± 7.0 55.1 ± 3.3 0.463
MC 50.3 ± 10.7 52.4 ± 8.8 0.494 50.1 ± 11.4 54.1 ± 9.4 0.156
HCV: hepatitis C group; FP: false-positive group; PF: physical functioning; PR: physical role; BP: bodily pain; GHP: general health perception; VIT:
vitality; SF: social functioning; ER: emotional role; MH: mental health; PC: physical component; MC: mental component.
Scores shown as means and standard deviation.
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Discussion
The HRQOL scores were quite similar between patients with
HBV and HCV and donors who presented false-positive results
at the time of the serological screening tests in phase 1 of
the study. Considering all donors were under the same stress
conditions (i.e., uncertainty about the likelihood of having a
health problem because they were recalled to repeat the sero-
logical tests), the stress of the investigation appeared to be
effectively reﬂected in the HRQOL. Compared to the HBV and
HCV groups, the false-positive controls showed improvement
in HRQOL scores after notiﬁcation that the conﬁrmatory tests
were negative (Time Point 2) and that they had no serologic
evidence of HBV, HCV or other transfusion-transmitted dis-
eases. The relief provided by the negative conﬁrmatory results
improved the HRQOL of the false-positive controls compared
to the group of donors with HBV and HCV. In this study, no
differences in HRQOL were found on comparing the HCV and
HBV groups at this very early stage of the disease because both
groups were subjected to the same stress due to uncertainty
regarding a possible infectious disease.
The choice of generic instruments or speciﬁc instruments
for liver disease in the assessment of the HRQOL was based
on its widespread use in Brazil, previous experience of the
study institution and the instruments’ reproducibility.15 Spe-
ciﬁc instruments to assess HRQOL linked to liver disease, such
as the Liver Disease Quality of Life Questionnaire, have been
validated and applied in this institution.16 However, these
instruments were not employed in this study because they
could not reliably be applied to blood donors without liver dis-
ease. In contrast, the SF-36 is useful and applicable both to
patients and to the general population.
In several studies on HRQOL in HCV, the starting point
was patients who had already received their diagnosis com-
pared with control groups in different stages of their disease.17
The originality of this evaluation was its longitudinal char-
acter that was designed to address the patients before and
after diagnoses of HBV or HCV. Unexpectedly, we observed
improvement in four out of eight domains in the summa-
rized SF-36 physical component scale from Time Point 1 to
Time Point 3 among HCV-positive donors. Thus, in contrast
to the hypothesis suggested by Groessl et al.,10 the knowl-
edge of the diagnosis did not lead to worsening of the HRQOL
in patients with HCV, but to an improvement. This percep-
tion of improved HRQOL was obtained by Time point 3 during
clinical care. The availability of adequate clinical monitor-
ing and a customized treatment with detailed explanations
of the evolution and prognosis may be responsible for the
improvement in HQROL.18 In fact, at this stage the main con-
cerns of donors were intensively addressed. These concerns
included doubts about the natural history of their illness, the
availability of treatment and the possibility of receiving free
medication and ongoing clinical support. Additionally, HCV
and HIV share major routes of transmission. Therefore, some
of the patients with HCV may have felt relieved at not being
HIV carriers because the latter is recognized as a much more
stigmatizing infection.
The lower HRQOL in Time point 1 may be related to
HCV causing fatigue and a reduced sense of well-being, as 2 0 1 5;3  7(6):381–387
demonstrated by Forton et al.19 Additionally, studies have
linked the decline in HRQOL to the presence of the virus in the
central nervous system.20 In later stages (especially in Time
point 3), there was an improvement in the HRQOL scores when
patients began their clinical follow-up. This increase may be
associated with stress relief due to knowing the real condi-
tion of their health, more  detailed knowledge regarding HCV
infection and the availability of antiviral therapy as mentioned
above. Indeed, it was previously demonstrated that there was
a decrease in HRQOL in patients with chronic HCV when the
diagnosis was transmitted by an unprepared medical staff.21
In contrast to HCV, the longitudinal analysis of the group
diagnosed with HBV showed no signiﬁcant differences in any
of the domains of the SF-36. Despite the prospect of a clini-
cal follow-up, issues related to the severity of the disease and
concerns about the transmission of a serious health problem
to their family and contacts may represent important com-
ponents that explain the low HRQOL.22 Moreover, patients
with HBV showed a worse HRQOL than the false-positive con-
trol group, especially during Time point 2. The lower HRQOL
scores in the HBV group and the false-positive control group
can be attributed to the initial stress caused by the necessity
of submission to a laboratory investigation of these donors.
The possibility of diagnosis of HIV infection may be a cause of
worry for most individuals who have to repeat the serological
tests; this concern may be associated with the emergence of
physical and emotional symptoms. A similar situation occurs
among blood donors who are diagnosed as HIV positive. Cleary
et al.23 demonstrated the development of symptoms and emo-
tional disorders among HIV-positive donors. In our population,
the nonspeciﬁc complaints of pain and feelings of malaise
reported during this phase may have decreased the health of
these individuals as a whole, thereby contributing to the drop
in their HRQOL scores.
Differences found in the longitudinal assessment of HBV
and HCV may be related to the different possibilities of viral
clearance for these two viruses.1 The current rates of elimina-
tion of HCV after treatment range from 50% to 85% of cases
according to the virus genotype. In chronic hepatitis B infec-
tion, the chances of serological clearance of the virus with
or without continuous treatment are smaller (approximately
10–30% of cases). The requirement for continuous care and
the therapeutic possibility of evolution to hepatocellular car-
cinoma even before the appearance of cirrhosis are relevant
concerns that can affect the HRQOL.24
There are some limitations in this study. First, there was a
considerable loss to follow-up along the course of the study.
The fear of having an infectious disease may have led some
donors not to attend the blood center at all phases of the study.
However, we  were able to recruit a sufﬁcient number of donors
to identify signiﬁcant differences in several domains of the
SF-36 both in the longitudinal analysis and in the compara-
tive analysis between the groups. Second, a participation bias
may have inﬂuenced our results. Participants may have been
more  concerned about their health than non-participants.
Consequently, the effects on HRQOL may be overestimated
among the participants. Finally, the control group was not nec-
essarily composed of healthy subjects because donors with
false-positive results may have an undiagnosed disease. Nev-
ertheless, our selection of false-positive donors as the control
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roup reduces the impact of recall bias because these donors
ere subjected to the same notiﬁcation, counseling, retesting,
nd systematic interview procedures as the cases.25
onclusions
he process of notiﬁcation and counseling can affect the
RQOL among healthy donors and those infected with HBV
nd HCV. In contrast to HBV carriers, the possibility of medi-
al treatment may improve the HRQOL of HCV-positive donors.
tudies that provide a broader knowledge of HRQOL among
ealthy and infected blood donors can aid the implementation
f public health policies not only by providing a broader and
ore  comprehensive approach by health professionals but
lso by promoting a more  digniﬁed and humanized approach
o these individuals.
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